Skip to main content

Table 4 Final staging

From: Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217)

 • Physical examination including oxygen saturation, performance status (ECOG), assessment of toxicity, concomitant medication

 • Laboratory tests (baseline panel), including free T4 and TSH and pregnancy test for women of childbearing potential

 • Echocardiography and ECG

 • Disease assessment by radiological imaging of the chest, abdomen, pelvis and all other sites of disease (CT/MRI-scan)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us